Open access · OA
via OpenAlex
Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies
Daniel Pedro Cardinali, Rüdiger Hardeland
Neuroendocrinology · 2016 · ▲ 130 citations
Abstract
The metabolic syndrome (MS) is a collection of risk factors for cardiovascular disease, including obesity, hypertension, hyperinsulinemia, glucose intolerance and dyslipidemia. MS is associated with low-grade inflammation of the white adipose tissue, which can subsequently lead to insulin resistance, impaired glucose tolerance and diabetes. Adipocytes secrete proinflammatory cytokines as well as leptin and trigger a vicious circle which leads to additional weight gain largely as fat. The imbalance between inflammatory and anti-inflammatory signals is crucial to aging. Healthy aging can benefit from melatonin, a compound known to possess direct and indirect antioxidant properties, to have a significant protective effect on mitochondrial function, to enhance circadian rhythm amplitudes, to modulate the immune system and to exhibit neuroprotective actions. Melatonin levels decrease in the course of senescence(definition) and are more strongly reduced in diseases related to insulin resistance. This short review article analyzes the multiple protective actions of melatonin that are relevant to the attenuation of inflammatory responses and progression of inflammaging(definition) and how melatonin is effective to curtail MS in animal models of hyperadiposity. The clinical data supporting the possible therapeutic use of melatonin in human MS are also reviewed. Since attention has been focused on the development of potent melatonin analogs with prolonged effects (ramelteon, agomelatine, tasimelteon, piromelatine) and in clinical trials these analogs were administered in doses considerably higher than those usually employed for melatonin, clinical trials on melatonin in the range of 50-100 mg/day are needed to further assess its therapeutic value in MS.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1159/000446543
- Canonical
- link ↗
- Fetched
- 2026-10-02 MST
Cite this
APA
Cardinali, D.P., & Hardeland, R. (2016). Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies. <em>Neuroendocrinology</em>. https://doi.org/10.1159/000446543
Vancouver
Cardinali DP, Hardeland R. Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies. Neuroendocrinology. 2016. doi:10.1159/000446543.
BibTeX
@article{daniel2016Inflam,
title = {Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies},
author = {Daniel Pedro Cardinali and Rüdiger Hardeland},
journal = {Neuroendocrinology},
year = {2016},
doi = {10.1159/000446543},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Antioxidants 2014
Open access · CC-BY
Melatonin Therapy in Patients with Alzheimer’s Disease
Rutgers, The State University of New Jersey 2023
Open access · US-GOV
Impact of Acute Exercise on Brain Insulin Sensitivity in Middle-aged to Older Adults
Journal of Diabetes Investigation 2013
Open access · OA
Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness
World Journal of Diabetes 2011
Open access · CC-BY
Assessing and treating insulin resistance in women with polycystic ovarian syndrome
Diabetologia 2008
Open access · OA
Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease
Cell Regeneration 2024
Open access · CC-BY